Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button

Home > Press > BioSante Pharmaceuticals to Present at Upcoming Conferences

Abstract:
BioSante Pharmaceuticals (AMEX: BPA) today announced that Stephen M. Simes, its president and CEO will present a corporate overview and update at two upcoming conferences. The conferences are:

* The Think Equity Partners' ThinkClinic: An Educational Forum for Healthcare Investors Conference on October 4, 2007 at 9:40 a.m. local time at the Pierre Hotel in New York.
* The Bio Investor Forum on October 10, 2007 at 11:15 a.m. local time at the Palace Hotel in San Francisco.

BioSante Pharmaceuticals to Present at Upcoming Conferences

LINCOLNSHIRE, IL | Posted on October 2nd, 2007

A live audio webcast of BioSante's presentation at these conferences can be accessed on the internet by visiting http://www.biosantepharma.com . An archive of these presentations will be available at the same address.

These conferences each feature companies presenting to a diverse group of investors, portfolio managers and analysts interested in the biotechnology and pharmaceuticals sectors as well as biotech and pharmaceutical company representatives.

####

About BioSante Pharmaceuticals
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development is Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.7 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including avian flu and biodefense vaccines, as well as a system for delivering drugs via alternative routes of administration and for aesthetic medicine.

For more information, please click here

Contacts:
BioSante Pharmaceuticals, Inc.
Phillip Donenberg
(847) 478-0500;

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Nanometrics Announces Upcoming Investor Events July 20th, 2016

Keystone Nano selected as a top scoring company by NCI investor review panel July 19th, 2016

Arrowhead Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference July 6th, 2016

Nanometrics to Participate in the 8th Annual CEO Investor Summit: Investor Event Held Concurrently with SEMICON West 2016 in San Francisco June 22nd, 2016

Nanomedicine

Scientists test nanoparticle drug delivery in dogs with osteosarcoma July 26th, 2016

The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins July 26th, 2016

Accurate design of large icosahedral protein nanocages pushes bioengineering boundaries: Scientists used computational methods to build ten large, two-component, co-assembling icosahedral protein complexes the size of small virus coats July 25th, 2016

New superconducting coil improves MRI performance: UH-led research offers higher resolution, shorter scan time July 23rd, 2016

Announcements

New lithium-oxygen battery greatly improves energy efficiency, longevity: New chemistry could overcome key drawbacks of lithium-air batteries July 26th, 2016

Scientists test nanoparticle drug delivery in dogs with osteosarcoma July 26th, 2016

Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016

Ultrasensitive sensor using N-doped graphene July 26th, 2016

Events/Classes

Nanometrics Announces Upcoming Investor Events July 20th, 2016

n-tech Research Announces August 3, 2016 Date for Smart Coatings Webinar July 18th, 2016

Instrumented Indentation Expert Addresses Trends with Industry Leaders: Leading nanoindentation expert hosts webinar discussing theory and practice of instrumented indentation July 14th, 2016

SUNY Poly Celebrates Its 10th Year Exhibiting at SEMICON West with Cutting Edge Developments in Integrated Photonics and Power Electronics July 8th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic